Renuka R. Nayak

The paper analyzes microbiome data from multiple cohorts to identify consistent signatures associated with methotrexate response in rheumatoid arthritis patients.

This study shows that the gut microbiome affects methotrexate pharmacology in mice and contributes to interindividual variation in drug metabolism and treatment outcomes.

This study shows that a ketogenic diet reduces autoimmune disease in mice by altering host metabolism and shaping gut microbiota, specifically through β-hydroxybutyrate and Lactobacillus species.

This study shows that methotrexate, a non-antibiotic drug, alters the human gut microbiota, favoring Firmicutes over Bacteroidetes, which correlates with improved drug response in rheumatoid arthritis patients.